HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 316 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,730 | -66.6% | 150 | -68.5% | 0.00% | – |
| Q2 2023 | $17,169 | +199.7% | 476 | +217.3% | 0.00% | – |
| Q1 2023 | $5,729 | -65.4% | 150 | -48.5% | 0.00% | – |
| Q4 2022 | $16,558 | +176.0% | 291 | +94.0% | 0.00% | – |
| Q3 2022 | $6,000 | -14.3% | 150 | 0.0% | 0.00% | – |
| Q2 2022 | $7,000 | +16.7% | 150 | 0.0% | 0.00% | – |
| Q1 2022 | $6,000 | 0.0% | 150 | 0.0% | 0.00% | – |
| Q4 2021 | $6,000 | -62.5% | 150 | -63.1% | 0.00% | – |
| Q3 2021 | $16,000 | +700.0% | 407 | +892.7% | 0.00% | – |
| Q4 2020 | $2,000 | -92.6% | 41 | -97.6% | 0.00% | – |
| Q3 2019 | $27,000 | +2600.0% | 1,734 | +5000.0% | 0.00% | – |
| Q2 2019 | $1,000 | -95.0% | 34 | -96.6% | 0.00% | – |
| Q1 2018 | $20,000 | +1900.0% | 1,000 | +1512.9% | 0.00% | – |
| Q4 2017 | $1,000 | -50.0% | 62 | -59.7% | 0.00% | – |
| Q2 2017 | $2,000 | – | 154 | +516.0% | 0.00% | – |
| Q3 2014 | $0 | -100.0% | 25 | -91.7% | 0.00% | – |
| Q2 2013 | $2,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 14,092,771 | $256,066,000 | 16.64% |
| BB BIOTECH AG | 8,247,860 | $149,864,000 | 3.97% |
| MSD Partners, L.P. | 2,245,000 | $40,792,000 | 3.07% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 428,633 | $5,969,000 | 2.84% |
| First Light Asset Management, LLC | 885,523 | $16,090,000 | 2.60% |
| SNYDER CAPITAL MANAGEMENT L P | 2,387,350 | $43,378,000 | 1.93% |
| Sterling Global Strategies LLC | 22,000 | $400,000 | 1.74% |
| Taylor Wealth Management Partners | 221,380 | $4,022,000 | 1.71% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 9,228,399 | $167,680,000 | 1.68% |
| DOHENY ASSET MANAGEMENT /CA | 124,393 | $2,260,000 | 1.18% |